Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M228,112Revenue $M58,831Net Margin (%)16.8Z-Score3.4
Enterprise Value $M241,337EPS $3.7Operating Margin %20.1F-Score6
P/E(ttm))25.0Cash Flow Per Share $0Pre-tax Margin (%)19.9Higher ROA y-yY
Price/Book3.410-y EBITDA Growth Rate %2.8Quick Ratio1.0Cash flow > EarningsY
Price/Sales4.25-y EBITDA Growth Rate %6.7Current Ratio1.3Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %-1.1ROA % (ttm)7.7Higher Current Ratio y-yY
Dividend Yield %2.9Insider Buy (3m)0ROE % (ttm)13.8Less Shares Outstanding y-yY
Payout Ratio %73.0Shares Outstanding M2,447ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 94.037%Add 10.04%51,102,219
NVSLee Ainslie 2014-06-30 Sold Out -0.42%$82.51 - $90.98
($87.73)
$ 94.037%Sold Out0
NVSLee Ainslie 2014-03-31 Add0.1%$78.2 - $83.82
($81.23)
$ 94.0316%Add 31.52%351,580
NVSPRIMECAP Management 2014-03-31 Reduce-0.26%$78.2 - $83.82
($81.23)
$ 94.0316%Reduce -10.13%24,014,586
NVSLee Ainslie 2013-12-31 Reduce-0.56%$72.96 - $80.39
($77.55)
$ 94.0321%Reduce -66.76%267,321
NVSLee Ainslie 2013-06-30 Add0.2%$68.42 - $75.5
($72.61)
$ 94.0330%Add 39.5%741,689
NVSJohn Hussman 2013-06-30 Reduce-0.52%$68.42 - $75.5
($72.61)
$ 94.0330%Reduce -47.49%218,900
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 94.0330%Sold Out0
NVSLee Ainslie 2013-03-31 Buy 0.49%$63.3 - $71.32
($67.87)
$ 94.0338%New holding, 531689 sh.531,689
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 94.0338%Reduce -85.39%726,200
NVSDodge & Cox 2012-12-31 Add0.11%$58.97 - $63.96
($61.79)
$ 94.0352%Add 2.65%48,438,459
NVSDodge & Cox 2012-09-30 Add0.12%$55.24 - $61.51
($58.49)
$ 94.0361%Add 3.23%47,187,759
NVSMario Gabelli 2012-03-31 Reduce$53.31 - $58.33
($52.37)
$ 94.0380%Reduce -37.42%11,740
NVSMichael Price 2012-03-31 Sold Out -1.3%$53.31 - $58.33
($52.37)
$ 94.0380%Sold Out0
NVSJohn Hussman 2012-03-31 Reduce-0.14%$53.31 - $58.33
($52.37)
$ 94.0380%Reduce -22.44%515,000
NVSMichael Price 2011-06-30 Buy 1.29%$54.23 - $64.52
($59.61)
$ 94.0358%New holding, 144969 sh.144,969
NVSVanguard Health Care Fund 2011-06-30 Add0.45%$54.23 - $64.52
($59.61)
$ 94.0358%Add 30.01%4,869,880
NVSMario Gabelli 2011-06-30 Add$54.23 - $64.52
($59.61)
$ 94.0358%Add 65.83%20,215
NVSMario Gabelli 2011-03-31 Reduce$52.75 - $59.24
($56.19)
$ 94.0367%Reduce -95.51%12,190
NVSVanguard Health Care Fund 2010-12-31 Reduce-0.42%$53.41 - $59.77
($57.3)
$ 94.0364%Reduce -21.07%4,869,880
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NVS Dodge & Cox 2014-06-3051,102,2192.094.4+10.04%
NVS Jean-Marie Eveillard 2014-06-3013,06000
NVS PRIMECAP Management 2014-06-3023,846,2360.972.4-0.7%
NVS Tweedy Browne 2014-06-30288,8250.010.56-0.92%
NVS John Hussman 2014-06-30214,0000.011.5-3.25%
NVS Mario Gabelli 2014-06-3010,24000-4.66%
NVS Lee Ainslie 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about NVS :

    Quarterly/Annual Reports about NVS:

      News about NVS:

      Articles On GuruFocus.com
      Why Investing Internationally Can Help Your Portfolio Sep 12 2014 
      Weekly 52-Week Highs Highlight: LLY, BG, NVS, HRL Sep 07 2014 
      Sarah Ketterer’s Causeway International Value Fund Reports Top Five Aug 31 2014 
      I Am Sure This Pharma-Company Suits Your Portfolio Aug 28 2014 
      A Strong Candidate for Investor´s Portfolios Aug 12 2014 
      Novartis: Ten Years of Solid ROE Jul 31 2014 
      Tweedy Browne Global Reports Their Second Quarter Portfolio Jul 18 2014 
      Sarah Ketterer’s Causeway International Value’s Top Five Holdings Jun 05 2014 
      Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks May 29 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 


      More From Other Websites
      Ebola under the microscope Sep 16 2014
      Novartis Presents Positive Data on Lucentis and Jetrea Sep 15 2014
      1:39 am Novartis demonstrates leadership in ophthalmology with new products and over 40 abstracts at... Sep 15 2014
      Novartis Presents Data on Multiple Sclerosis Drug Gilenya Sep 11 2014
      Receptos MS Drug Yields More Good Data; Stock Jumps Sep 10 2014
      Novartis (NVS) Presents Positive Data on Ultibro Breezhaler Sep 08 2014
      Blockbusters Differentiate Novartis Sep 05 2014
      Novartis Offers Healthy Gains at a Bargain Stock Price Sep 05 2014
      The Market's Roses, Thorns, and All Time Highs... Sep 03 2014
      Novartis, Regeneron Shares Advance To New Highs On Updated Drug News Sep 02 2014
      Today's Thorns, Roses and All Time Highs in the Markets... Sep 02 2014
      Novartis Releases Positive Data on LCZ696 for Heart Failure Sep 02 2014
      [$$] Blockbuster Expectations for Novartis' Heart Drug Sep 02 2014
      Why Novartis AG (NVS) Stock Is Climbing Today Sep 02 2014
      Novartis' Game Changer: When Failure Turns To Success Sep 02 2014
      Novartis Japan admits concealing drug side effects Sep 01 2014
      Heart Drug Study Gives Novartis a Shot in the Arm Sep 01 2014
      Novartis Japan admits concealing drug side effects Sep 01 2014
      Novartis Rises Most in Five Months on Heart-Drug Trial Sep 01 2014
      Heart drug launch could be "most exciting ever", says Novartis Aug 31 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK